Abstract 1382
Background
Glioblastoma (GBM) is well known as the most common primary aggressive malignant brain tumor of the CNS and became one of the most lethal forms of cancer in human. The prognosis for patients with GBM is very poor. Current treatment options for recurrent GBM are very limited. Apatinib, a novel small molecular anti-angiogenic inhibitor, can highly selectively bind VEGFR-2 and inhibit its activation to block VEGF mediated the signal transduction and inhibit the angiogenesis to control the growth of the tumors. We hypothesized that apatinib combined with dose-dense TMZ could lead to prolonged 6-month PFS and/or OS. We also assessed toxicity and tolerability.
Methods
Patients with recurrent glioblastoma were enrolled in this study. Patients were treated with concurrent treatment of apatinib (500mg qd) and dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) until disease progression or intolerable toxicity. The efficacy was evaluated using RANO high-grade glioma criteria. The safety was assessed via NCI-CTCAE 4.0. Survival was estimated with Kaplan-Meier curve and log-rank test.
Results
From March 2016 to January 2018, twenty eligible patients who had relapsed from the standard chemoradiotherapy regimen were enrolled in this study. 35% were female and the median ages were 50.5 years. The median KPS score before treatment was 70. Median follow-up time was 12 months. KPS scores improved in 60%(12/20) of patients after treatment. In total, there were 1 with CR, 8 with PR, 9 with SD, and 2 with PD. Three patients were still alive. The ORR was 45% (9/20) and the DCR was 90% (18/20). The median PFS for all patients were 6 months (95% confidence interval [CI]: 5.3m to 7.8m). Median OS is 9.3 months (95% CI, 8.2m–12.2m). The most common treatment-related adverse events (AEs) were hypertension (20.9%), hand-foot syndrome (16.3%), leukopenia (14.0%), The grade 3/4 adverse events included hypertension (4.7%), leukopenia (2.3%), thrombocytopenia (2.3%).
Conclusions
Apatinib combined with dose-dense temozolomide seems to be a promising therapeutic option for recurrent glioblastoma with acceptable toxicity profiles. Clinical randomized controlled trial is warranted to be designed to confirm the results.
Clinical trial identification
NCT03660761.
Editorial acknowledgement
Baoyan Liu (Shandong Medical Biotechnological Center, School of Medicine and Life Science, Shandong Academy of Medical Sciences, University of Jinan) provided assistance with manuscript editing.
Legal entity responsible for the study
Shandong Cancer Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2185 - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Presenter: Wolfgang Brückl
Session: Poster Display session 1
Resources:
Abstract
1524 - Effectiveness of sequencing TKIs in patients with EGFR mutation-positive Non-small-Cell Lung Cancer (NSCLC): A French National medico administrative claim database analysis
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
5733 - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
Presenter: Tae Min Kim
Session: Poster Display session 1
Resources:
Abstract
5440 - Different stories for different EGFR exon 19 deletion variants
Presenter: Chao Zhao
Session: Poster Display session 1
Resources:
Abstract
2982 - Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy
Presenter: Yuan-Kai Shi
Session: Poster Display session 1
Resources:
Abstract
4002 - Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study
Presenter: Maximilian Hochmair
Session: Poster Display session 1
Resources:
Abstract
2941 - Treatment patterns of EGFR mt+ NSCLC IV pts: Real world data of the NOWEL network
Presenter: Julia Roeper
Session: Poster Display session 1
Resources:
Abstract
4154 - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment
Presenter: Matteo Canale
Session: Poster Display session 1
Resources:
Abstract
1175 - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Presenter: Kimio Yonesaka
Session: Poster Display session 1
Resources:
Abstract
2023 - Patients with brain metastases treated with afatinib in clinical practice – results from the prospective non-interventional study GIDEON
Presenter: Eckart Laack
Session: Poster Display session 1
Resources:
Abstract